<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588403</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2018-133</org_study_id>
    <nct_id>NCT03588403</nct_id>
  </id_info>
  <brief_title>TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>Comparison of Tomotherapy Versus Intensity-modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma: a Prospective,Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tomotherapy is a new radiation planning and delivery technology which may allow for delivery
      of higher radiation doses with less damage to normal tissues. The investigators aim to
      compare the treatment efficacy and quality of life between tomotherapy and
      intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QoL(quality of life)</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in quality of life were assessed by EORTC QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS (progression free survival)</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of therapy to the date of disease progression or death from any cause, whichever was first (according the criterion of RECIST 1.1 ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of therapy to death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRRFS(Locoregional failure-free survival)</measure>
    <time_frame>2 years</time_frame>
    <description>from the first day of therapy to the date of first locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 50 days and every 3 months thereafter for 5 years. Observe and record the toxicity profile (including but not limit to mucositis, liver and kidney function, et al.) according NCI-CTCAE 4.03 during the chemoradiation and follow-up.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A:Tomotherapy</arm_group_label>
    <description>Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: IMRT</arm_group_label>
    <description>Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TOMO</intervention_name>
    <description>Tomotherapy</description>
    <arm_group_label>Arm A:Tomotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Intensity modulated radiotherapy</description>
    <arm_group_label>Arm B: IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        nasopharyngeal carcinoma patients staged T1-4N0-3M0
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly histologically confirmed non-keratinizing carcinoma.

          2. Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system）

          3. Performance status: KPS&gt;70

          4. With normal liver function test (ALT, AST &lt;1.5ULN)

          5. Renal: creatinine clearance &gt;60ml/min

          6. Without hematopathy,marrow: WBC &gt;4*109/L, HGB&gt;80G/L, and PLT&gt;100*109/L.

          7. Written informed consent

        Exclusion Criteria:

          1. WHO type I squamous cell carcinoma or adenocarcinoma

          2. Age &gt;65 or &lt;18

          3. Prior malignancy (except adequately treated carcinoma in-situ of the cervix or
             basal/squamous cell carcinoma of the skin)

          4. Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside
             the intended RT treatment volume)

          5. Patient is pregnant or lactating

          6. Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Xiaozhong Chen</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>+86-571-88128202</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Chen Xiaozhong</investigator_full_name>
    <investigator_title>chief phisician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

